Identification

Name
Loratadine
Accession Number
DB00455  (APRD00384)
Type
Small Molecule
Groups
Approved, Investigational
Description

Loratadine is a derivative of azatadine and a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (histamine H1 antagonists) it lacks central nervous system depressing effects such as drowsiness. [PubChem]

Structure
Thumb
Synonyms
  • Loratadina
  • Loratadinum
External IDs
SCH-29851
Product Images
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LoratadineTablet10 mg/1OralNorthwind Pharmaceuticals2014-10-27Not applicableUs
Loratadine Allergy ReliefTablet10 mg/1OralClinical Solutions Wholsesale2003-08-282017-07-03Us
Loratadine antihistamineTablet10 mg/1Oralbryant ranch prepack2008-10-15Not applicableUs
Loratadineantihistamine antihistamineTablet10 mg/1OralRemedy Repack2013-05-20Not applicableUs
Loratadineantihistamine antihistamineTablet10 mg/1OralRemedy Repack2014-02-062017-01-25Us
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
24 Hour Allergy ReliefTablet10 mg/1OralMeijer Distribution2014-12-30Not applicableUs
24 Hour Allergy RemedyTablet10 mgOralVita Health Products Inc2006-07-28Not applicableCanada
7 Select Allergy ReliefTablet10 mg/1Oral7 Eleven2014-05-14Not applicableUs
Alavert AllergyTablet, orally disintegrating10 mg/1OralWyeth Consumer Healthcare Llc2002-12-19Not applicableUs
Alavert AllergyTablet, orally disintegrating10 mg/1OralWyeth Consumer Healthcare Llc2002-12-19Not applicableUs
Allegy Relief 24 hour non drowsyTablet10 mg/1OralHannaford Brothers Company2006-09-072017-12-22Us
AllergyTablet10 mg/1OralRemedy Repack2017-10-11Not applicableUs
AllergyTablet10 mg/1OralMajor2005-02-21Not applicableUs
AllergyTablet10 mg/1OralSelder, S.A. de C.V.2014-12-16Not applicableUs
Allergy ChildrensLiquid5 mg/5mLOralMeijer2018-02-28Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
12 Hour Allergy and CongestionLoratadine (5 mg/1) + Pseudoephedrine sulfate (120 mg/1)Tablet, film coated, extended releaseOralWalgreen2018-05-05Not applicableUs
Alavert Allergy Sinus D-12Loratadine (5 mg/1) + Pseudoephedrine sulfate (120 mg/1)Tablet, film coated, extended releaseOralWyeth Ltd.2004-01-30Not applicableUs00573 2660 24 nlmimage10 8d46c6b6
Allerclear-D 24 HourLoratadine (10 mg/1) + Pseudoephedrine sulfate (240 mg/1)Tablet, extended releaseOralCostco Wholesale2016-03-012018-04-30Us
Allergy and Congestion ReliefLoratadine (10 mg/1) + Pseudoephedrine sulfate (240 mg/1)Tablet, film coatedOralHannaford Brothers Company2009-06-032017-12-22Us
Allergy and Congestion ReliefLoratadine (10 mg/1) + Pseudoephedrine sulfate (240 mg/1)Tablet, extended releaseOralHyvee2003-06-302018-04-05Us
Allergy and Congestion ReliefLoratadine (5 mg/1) + Pseudoephedrine sulfate (120 mg/1)Tablet, film coated, extended releaseOralL. Perrigo Company2018-04-12Not applicableUs
Allergy and congestion reliefLoratadine (5 mg/1) + Pseudoephedrine sulfate (120 mg/1)Tablet, extended releaseOralKroger2012-04-06Not applicableUs
Allergy and Congestion ReliefLoratadine (5 mg/1) + Pseudoephedrine sulfate (120 mg/1)Tablet, extended releaseOralL. Perrigo Company2012-01-23Not applicableUs
Allergy and Congestion ReliefLoratadine (5 mg/1) + Pseudoephedrine sulfate (120 mg/1)Tablet, film coated, extended releaseOralKroger2018-05-18Not applicableUs
Allergy and Congestion ReliefLoratadine (5 mg/1) + Pseudoephedrine sulfate (120 mg/1)Tablet, extended releaseOralHyvee2012-03-192017-12-22Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Help I have allergiesLoratadine (10 mg/1)TabletOralHelp Remedies, Inc.2009-07-01Not applicableUs
LoratadineLoratadine (10 mg/1)TabletOralRebel Distributors2010-01-21Not applicableUs51660 0526 05 nlmimage10 bf16dfa6
LoratadineLoratadine (10 mg/1)TabletOralCardinal Health2013-06-14Not applicableUs
International/Other Brands
Aerotina / Alavert / Biloina / Civeran / Claritin / Fristamin / Histaloran / Lomilan / Loracert / Loradex / Loranox / Lorastine / Loratyne / Loritine / Nularef / Restamine / Roletra / Sensibit
Categories
UNII
7AJO3BO7QN
CAS number
79794-75-5
Weight
Average: 382.883
Monoisotopic: 382.144805697
Chemical Formula
C22H23ClN2O2
InChI Key
JCCNYMKQOSZNPW-UHFFFAOYSA-N
InChI
InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3
IUPAC Name
ethyl 4-{13-chloro-4-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene}piperidine-1-carboxylate
SMILES
CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2

Pharmacology

Indication

A self-medication that is used alone or in combination with pseudoephedrine sulfate for the symptomatic relief of seasonal allergic rhinitis. Also used for the symptomatic relief of pruritus, erythema, and urticaria associated with chronic idiopathic urticaria in patients (not for children under 6 unless directed by a clincian).

Associated Conditions
Pharmacodynamics

Loratadine is a long acting second generation antihistamine that is similar in structure to cyproheptadine and azatadine. The pharmacology of loratadine is similar to other antihistamines, but unlike other H1-blockers, loratidine is shown to exhibit competitive, specific, and selective antagonism of H1 receptors. The exact mechanism of this interaction is unknown, but disposition of the drug suggests that loratadine's prolonged antagonism of histamine may be due to the drug's slow dissociation from the receptor or the formation of the active metabolite, desloratadine. Loratadine does not penetrate the CNS effectively and has a low affinity for CNS H1-receptors.

Mechanism of action

Loratadine competes with free histamine and exhibits specific, selective peripheral H1 antagonistic activity. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine. Loratadine has low affinity for cholinergic receptors and does not exhibit any appreciable alpha-adrenergic blocking activity in-vitro. Loratadine also appears to suppress the release of histamine and leukotrienes from animal mast cells, and the release of leukotrienes from human lung fragments, although the clinical importance of this is unknown.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
UPotassium voltage-gated channel subfamily H member 2Not AvailableHuman
Absorption

Rapidly absorbed following oral administration (40% bioavailability)

Volume of distribution
Not Available
Protein binding

97-99%

Metabolism

Hepatic

Route of elimination
Not Available
Half life

8.4 hours

Clearance
Not Available
Toxicity

somnolence, tachycardia, and headache LD50=mg/kg (orally in rat)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Loratadine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Loratadine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Loratadine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative and stimulatory activities of Loratadine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Loratadine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Loratadine is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Loratadine is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Loratadine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Loratadine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Loratadine.Approved, Investigational
AbexinostatThe risk or severity of QTc prolongation can be increased when Abexinostat is combined with Loratadine.Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Loratadine.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Loratadine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Loratadine is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Loratadine is combined with Acetylglycinamide chloral hydrate.Experimental
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Loratadine.Approved, Vet Approved
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Loratadine.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Loratadine is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Loratadine is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Loratadine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Loratadine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Loratadine is combined with Alaproclate.Experimental
AlcaftadineThe risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Loratadine.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Loratadine is combined with Alcuronium.Experimental
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Loratadine.Experimental, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Loratadine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Loratadine.Approved, Illicit
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Loratadine.Approved, Investigational
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with Loratadine.Approved, Vet Approved
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Loratadine.Approved, Investigational
AllobarbitalThe risk or severity of adverse effects can be increased when Loratadine is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Loratadine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Loratadine is combined with Almotriptan.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Loratadine is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Loratadine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Loratadine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Loratadine.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Loratadine is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Loratadine is combined with Alverine.Approved, Investigational
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Loratadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Loratadine.Approved, Investigational
AmifampridineThe risk or severity of QTc prolongation can be increased when Amifampridine is combined with Loratadine.Approved
AmikacinThe risk or severity of adverse effects can be increased when Loratadine is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Loratadine is combined with Amineptine.Illicit, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Loratadine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Loratadine.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Loratadine is combined with Amitriptylinoxide.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Loratadine.Approved, Illicit
AmodiaquineThe risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Loratadine.Approved, Investigational
AmoxapineThe risk or severity of QTc prolongation can be increased when Amoxapine is combined with Loratadine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Loratadine is combined with Amperozide.Experimental
AmphetamineAmphetamine may decrease the sedative and stimulatory activities of Loratadine.Approved, Illicit, Investigational
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Loratadine.Approved, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Anagrelide.Approved
AniracetamThe risk or severity of adverse effects can be increased when Loratadine is combined with Aniracetam.Experimental
AntazolineThe risk or severity of QTc prolongation can be increased when Antazoline is combined with Loratadine.Approved
ApalutamideThe serum concentration of Loratadine can be decreased when it is combined with Apalutamide.Approved, Investigational
APD791The risk or severity of adverse effects can be increased when Loratadine is combined with APD791.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Loratadine.Approved
ApomorphineThe risk or severity of QTc prolongation can be increased when Apomorphine is combined with Loratadine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Loratadine is combined with Apramycin.Experimental, Vet Approved
AprepitantThe serum concentration of Loratadine can be increased when it is combined with Aprepitant.Approved, Investigational
AprobarbitalThe risk or severity of adverse effects can be increased when Loratadine is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Loratadine is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Loratadine is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Loratadine is combined with Arbekacin.Approved, Investigational
ArformoterolThe risk or severity of QTc prolongation can be increased when Arformoterol is combined with Loratadine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Loratadine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Loratadine.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Artemether.Approved
Ascorbic acidThe serum concentration of Ascorbic acid can be increased when it is combined with Loratadine.Approved, Nutraceutical
AsenapineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Asenapine.Approved
AstemizoleThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Loratadine.Approved, Investigational, Withdrawn
AtazanavirThe risk or severity of QTc prolongation can be increased when Atazanavir is combined with Loratadine.Approved, Investigational
AtomoxetineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Loratadine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Loratadine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Loratadine is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Loratadine is combined with Atracurium besylate.Approved
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Loratadine.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Loratadine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Azaperone.Investigational, Vet Approved
AzatadineThe risk or severity of QTc prolongation can be increased when Azatadine is combined with Loratadine.Approved
AZD-3043The risk or severity of adverse effects can be increased when Loratadine is combined with AZD-3043.Investigational
AzelastineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe risk or severity of QTc prolongation can be increased when Azithromycin is combined with Loratadine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Loratadine.Approved
BarbexacloneThe risk or severity of adverse effects can be increased when Loratadine is combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Loratadine is combined with Barbital.Illicit
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Loratadine.Approved, Investigational
BeclamideThe risk or severity of adverse effects can be increased when Loratadine is combined with Beclamide.Experimental
BedaquilineThe risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Loratadine.Approved
BekanamycinThe risk or severity of adverse effects can be increased when Loratadine is combined with Bekanamycin.Experimental
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Loratadine.Approved, Investigational
BenactyzineThe risk or severity of adverse effects can be increased when Loratadine is combined with Benactyzine.Withdrawn
BenmoxinThe risk or severity of adverse effects can be increased when Loratadine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Loratadine is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Loratadine.Approved
BenzoctamineThe risk or severity of adverse effects can be increased when Loratadine is combined with Benzoctamine.Approved
BenzphetamineBenzphetamine may decrease the sedative and stimulatory activities of Loratadine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Loratadine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineLoratadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Loratadine.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Loratadine.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Loratadine.Approved, Vet Approved
BifemelaneThe risk or severity of adverse effects can be increased when Loratadine is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Loratadine is combined with Bifeprunox.Investigational
BilastineThe risk or severity of QTc prolongation can be increased when Bilastine is combined with Loratadine.Approved, Investigational
BL-1020The risk or severity of adverse effects can be increased when Loratadine is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Loratadine is combined with Blonanserin.Approved, Investigational
BoceprevirThe metabolism of Loratadine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Loratadine.Approved, Investigational
BosentanThe serum concentration of Loratadine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Loratadine.Approved
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Loratadine is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Loratadine is combined with Botulinum Toxin Type B.Approved, Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Loratadine.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Loratadine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Loratadine is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Loratadine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Loratadine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Loratadine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Loratadine is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Loratadine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Loratadine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Loratadine is combined with Brotizolam.Approved, Investigational, Withdrawn
BuclizineThe risk or severity of QTc prolongation can be increased when Buclizine is combined with Loratadine.Approved
BufotenineThe risk or severity of adverse effects can be increased when Loratadine is combined with Bufotenine.Experimental, Illicit
BuprenorphineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Loratadine is combined with Bupropion.Approved
BuserelinThe risk or severity of QTc prolongation can be increased when Buserelin is combined with Loratadine.Approved, Investigational
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Loratadine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Loratadine.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Loratadine.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Loratadine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Loratadine.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of QTc prolongation can be increased when Butriptyline is combined with Loratadine.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Loratadine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Loratadine is combined with Cabergoline.Approved
CamazepamThe risk or severity of adverse effects can be increased when Loratadine is combined with Camazepam.Approved, Illicit
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Loratadine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Loratadine.Approved
CannabidiolThe risk or severity of adverse effects can be increased when Loratadine is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Loratadine is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Loratadine is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Loratadine is combined with Captodiame.Approved, Investigational
CarbamazepineThe metabolism of Loratadine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Loratadine.Approved
CarbromalThe risk or severity of adverse effects can be increased when Loratadine is combined with Carbromal.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Loratadine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Loratadine.Approved, Investigational
CariprazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Loratadine is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Loratadine.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Caroxazone.Withdrawn
CathinoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Cathinone.Illicit
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Loratadine.Approved, Investigational
CeritinibThe serum concentration of Loratadine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Loratadine.Approved, Withdrawn
CerlapirdineThe risk or severity of adverse effects can be increased when Loratadine is combined with Cerlapirdine.Investigational
Cerliponase alfaThe serum concentration of Cerliponase alfa can be increased when it is combined with Loratadine.Approved, Investigational
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Loratadine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Loratadine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlorambucilThe serum concentration of Chlorambucil can be increased when it is combined with Loratadine.Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Loratadine.Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Loratadine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of QTc prolongation can be increased when Chloroquine is combined with Loratadine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Loratadine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Loratadine is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphentermineChlorphentermine may decrease the sedative and stimulatory activities of Loratadine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Loratadine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Loratadine.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Loratadine is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Loratadine.Approved
CilansetronThe risk or severity of adverse effects can be increased when Loratadine is combined with Cilansetron.Investigational
CilostazolThe risk or severity of QTc prolongation can be increased when Cilostazol is combined with Loratadine.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Loratadine.Approved, Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Loratadine is combined with Cinitapride.Approved, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Loratadine.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Loratadine is combined with Cinolazepam.Approved
CinoxacinThe risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Loratadine.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Loratadine.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Loratadine is combined with Cisatracurium.Approved
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Loratadine.Approved
CitalopramThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Citalopram.Approved
ClarithromycinThe risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Loratadine.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Loratadine is combined with Clidinium.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Loratadine is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Loratadine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Loratadine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of QTc prolongation can be increased when Clomipramine is combined with Loratadine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Loratadine is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Loratadine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Loratadine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Loratadine is combined with Clopenthixol.Experimental
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Loratadine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Loratadine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Loratadine is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Loratadine is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Loratadine can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxazolamThe risk or severity of adverse effects can be increased when Loratadine is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of QTc prolongation can be increased when Clozapine is combined with Loratadine.Approved
CobicistatThe metabolism of Loratadine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Loratadine.Approved, Investigational
CocaineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Loratadine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Loratadine.Approved
ColistimethateThe risk or severity of adverse effects can be increased when Loratadine is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Loratadine is combined with Colistin.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Loratadine.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Loratadine.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Loratadine.Approved, Investigational
CrizotinibThe risk or severity of QTc prolongation can be increased when Crizotinib is combined with Loratadine.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Loratadine.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Loratadine.Investigational
CurcuminThe metabolism of Loratadine can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of QTc prolongation can be increased when Cyclizine is combined with Loratadine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Loratadine is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Loratadine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Loratadine is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Loratadine is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Loratadine.Approved
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Loratadine.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Loratadine.Approved
DabrafenibThe serum concentration of Loratadine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Loratadine.Approved, Investigational
DanazolThe metabolism of Loratadine can be decreased when combined with Danazol.Approved
DantroleneThe risk or severity of adverse effects can be increased when Loratadine is combined with Dantrolene.Approved, Investigational
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Loratadine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Loratadine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Loratadine can be decreased when combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Loratadine.Approved
DasatinibThe serum concentration of Loratadine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Loratadine.Approved
DeanolThe risk or severity of adverse effects can be increased when Loratadine is combined with Deanol.Experimental
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Loratadine.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Loratadine is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Loratadine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixThe risk or severity of QTc prolongation can be increased when Degarelix is combined with Loratadine.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Delamanid is combined with Loratadine.Approved, Investigational
DelavirdineThe metabolism of Loratadine can be decreased when combined with Delavirdine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Loratadine is combined with Delorazepam.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Loratadine is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Loratadine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of QTc prolongation can be increased when Desflurane is combined with Loratadine.Approved
DesipramineThe risk or severity of QTc prolongation can be increased when Desipramine is combined with Loratadine.Approved, Investigational
DesloratadineThe risk or severity of QTc prolongation can be increased when Desloratadine is combined with Loratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Loratadine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Loratadine is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Deutetrabenazine.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Loratadine.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Loratadine.Approved
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Loratadine.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Loratadine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Loratadine is combined with Dexmethylphenidate.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Loratadine is combined with Dextofisopam.Investigational
DextroamphetamineDextroamphetamine may decrease the sedative and stimulatory activities of Loratadine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Loratadine is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Loratadine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Loratadine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Loratadine.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Loratadine is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Loratadine is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Dichloralphenazone.Approved, Illicit
Diethyl etherThe risk or severity of adverse effects can be increased when Loratadine is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Loratadine.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Loratadine.Approved, Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Loratadine is combined with Difenoxin.Approved, Illicit
DifloxacinThe risk or severity of QTc prolongation can be increased when Difloxacin is combined with Loratadine.Vet Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Loratadine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Loratadine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Loratadine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Loratadine is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe metabolism of Loratadine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Loratadine.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dimethyltryptamine.Experimental, Illicit
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Loratadine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Loratadine.Approved, Illicit
DisopyramideThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dixyrazine.Experimental
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Loratadine.Approved, Investigational
DofetilideThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Dofetilide.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Dolasetron is combined with Loratadine.Approved, Investigational
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Loratadine.Approved
Domoic AcidThe risk or severity of adverse effects can be increased when Loratadine is combined with Domoic Acid.Experimental
DomperidoneThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of QTc prolongation can be increased when Donepezil is combined with Loratadine.Approved
DopamineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Loratadine is combined with Doramectin.Vet Approved
DosulepinThe risk or severity of QTc prolongation can be increased when Dosulepin is combined with Loratadine.Approved
DotarizineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dotarizine.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Loratadine is combined with Doxacurium.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Loratadine is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of QTc prolongation can be increased when Doxepin is combined with Loratadine.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Loratadine.Approved, Investigational
DoxycyclineThe metabolism of Loratadine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Loratadine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved, Illicit
DronedaroneThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Loratadine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Loratadine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dyclonine.Approved
EbastineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Loratadine.Approved, Investigational
EcopipamThe risk or severity of adverse effects can be increased when Loratadine is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Loratadine is combined with Edivoxetine.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Loratadine.Approved
EfavirenzThe metabolism of Loratadine can be decreased when combined with Efavirenz.Approved, Investigational
ElagolixThe serum concentration of Elagolix can be increased when it is combined with Loratadine.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Loratadine.Approved
EletriptanThe risk or severity of adverse effects can be increased when Loratadine is combined with Eletriptan.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Loratadine is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Eltoprazine.Investigational
EmedastineThe risk or severity of QTc prolongation can be increased when Emedastine is combined with Loratadine.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Loratadine is combined with Emepronium.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Loratadine is combined with Emylcamate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Loratadine is combined with Enflurane.Approved, Investigational, Vet Approved
EnoxacinThe risk or severity of QTc prolongation can be increased when Enoxacin is combined with Loratadine.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Loratadine is combined with Entacapone.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Entinostat is combined with Loratadine.Investigational
EnzalutamideThe serum concentration of Loratadine can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of QTc prolongation can be increased when Epinastine is combined with Loratadine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Loratadine is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Loratadine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ergotamine.Approved
EribulinThe risk or severity of QTc prolongation can be increased when Eribulin is combined with Loratadine.Approved, Investigational
ErlotinibThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Erlotinib.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Loratadine.Approved, Investigational
ErythromycinThe risk or severity of QTc prolongation can be increased when Erythromycin is combined with Loratadine.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Loratadine is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Loratadine is combined with Esmirtazapine.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Loratadine is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Loratadine.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Loratadine.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Loratadine.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Loratadine.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Loratadine.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Loratadine.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Loratadine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Loratadine.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Loratadine.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Loratadine.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Loratadine is combined with Etacrynic acid.Approved, Investigational
EthadioneThe risk or severity of adverse effects can be increased when Loratadine is combined with Ethadione.Experimental
EthanolLoratadine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Loratadine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Loratadine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Loratadine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Loratadine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Loratadine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Loratadine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Loratadine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Loratadine is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Loratadine is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Loratadine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Loratadine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Etoperidone.Withdrawn
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Loratadine.Approved
EtorphineThe risk or severity of adverse effects can be increased when Loratadine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Loratadine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Loratadine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Loratadine.Approved
EzogabineThe risk or severity of QTc prolongation can be increased when Ezogabine is combined with Loratadine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Loratadine is combined with Fabomotizole.Experimental
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Loratadine.Approved
Fazadinium bromideThe risk or severity of adverse effects can be increased when Loratadine is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Loratadine is combined with Febarbamate.Experimental
FelbamateThe risk or severity of QTc prolongation can be increased when Felbamate is combined with Loratadine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Loratadine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Loratadine is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Loratadine.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Loratadine is combined with Fenyramidol.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Loratadine.Approved
FexofenadineThe risk or severity of QTc prolongation can be increased when Fexofenadine is combined with Loratadine.Approved, Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Loratadine.Approved
FingolimodThe risk or severity of QTc prolongation can be increased when Fingolimod is combined with Loratadine.Approved, Investigational
FlecainideThe risk or severity of QTc prolongation can be increased when Flecainide is combined with Loratadine.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Loratadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Loratadine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Fluanisone.Experimental
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Loratadine.Approved
FluconazoleThe risk or severity of QTc prolongation can be increased when Fluconazole is combined with Loratadine.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Loratadine is combined with Fludiazepam.Approved, Illicit
FlumequineThe risk or severity of QTc prolongation can be increased when Flumequine is combined with Loratadine.Withdrawn
FlunarizineThe risk or severity of adverse effects can be increased when Loratadine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Loratadine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Loratadine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Loratadine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Loratadine is combined with Fluspirilene.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Loratadine.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Loratadine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Loratadine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Loratadine is combined with Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of QTc prolongation can be increased when Formoterol is combined with Loratadine.Approved, Investigational
FosamprenavirThe metabolism of Loratadine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Loratadine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetThe risk or severity of QTc prolongation can be increased when Foscarnet is combined with Loratadine.Approved
FosphenytoinThe metabolism of Loratadine can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Loratadine is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Loratadine is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Loratadine is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Furazolidone.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Loratadine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Loratadine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Loratadine is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Loratadine is combined with Gaboxadol.Investigational
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Loratadine.Approved, Investigational
GalantamineThe risk or severity of QTc prolongation can be increased when Galantamine is combined with Loratadine.Approved
GallamineThe risk or severity of adverse effects can be increased when Loratadine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Loratadine is combined with Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Loratadine.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Loratadine is combined with Gantacurium Chloride.Investigational
GarenoxacinThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Loratadine.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Loratadine.Approved, Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Loratadine is combined with Gedocarnil.Experimental
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Loratadine.Approved, Investigational
GemifloxacinThe risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Loratadine.Approved, Investigational
GeneticinThe risk or severity of adverse effects can be increased when Loratadine is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Loratadine is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Loratadine is combined with GENTAMICIN C1A.Experimental
GepefrineGepefrine may decrease the sedative and stimulatory activities of Loratadine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Loratadine is combined with Gepirone.Investigational
GivinostatThe risk or severity of QTc prolongation can be increased when Givinostat is combined with Loratadine.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Loratadine.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Loratadine is combined with Glutethimide.Approved, Illicit
GoserelinThe risk or severity of QTc prolongation can be increased when Goserelin is combined with Loratadine.Approved
Gramicidin DThe serum concentration of Gramicidin D can be increased when it is combined with Loratadine.Approved
GranisetronThe risk or severity of QTc prolongation can be increased when Granisetron is combined with Loratadine.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Loratadine.Approved
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Loratadine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Loratadine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Halofantrine.Approved
HaloperidolThe risk or severity of QTc prolongation can be increased when Haloperidol is combined with Loratadine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Loratadine is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Loratadine is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Loratadine is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Loratadine is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Loratadine is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Loratadine is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Loratadine is combined with Hexapropymate.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Loratadine is combined with Hexobarbital.Approved
HistrelinThe risk or severity of QTc prolongation can be increased when Histrelin is combined with Loratadine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Loratadine.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Hydracarbazine.Experimental
HydrocodoneLoratadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Loratadine.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Loratadine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative and stimulatory activities of Loratadine.Approved
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Loratadine.Approved
HydroxyureaThe serum concentration of Hydroxyurea can be increased when it is combined with Loratadine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Loratadine is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Loratadine is combined with Hypericin.Investigational
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Loratadine.Approved, Investigational
IbutilideThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Ibutilide.Approved
IdalopirdineThe risk or severity of adverse effects can be increased when Loratadine is combined with Idalopirdine.Investigational
IdelalisibThe metabolism of Loratadine can be decreased when combined with Idelalisib.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Loratadine is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Loratadine is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Iloperidone.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Loratadine is combined with Imagabalin.Investigational
ImatinibThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Imatinib.Approved
ImipramineThe risk or severity of QTc prolongation can be increased when Imipramine is combined with Loratadine.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Loratadine is combined with Imipramine oxide.Experimental
IndacaterolThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Loratadine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Loratadine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of QTc prolongation can be increased when Indapamide is combined with Loratadine.Approved
IndinavirThe metabolism of Loratadine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Loratadine is combined with Indiplon.Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Loratadine.Approved, Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative and stimulatory activities of Loratadine.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Loratadine is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Loratadine is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Loratadine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Loratadine is combined with Iproniazid.Withdrawn
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Loratadine.Approved, Investigational
IsavuconazoleThe serum concentration of Loratadine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Loratadine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Loratadine is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Loratadine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of QTc prolongation can be increased when Isoflurane is combined with Loratadine.Approved, Vet Approved
IsoniazidThe metabolism of Loratadine can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Loratadine.Approved, Investigational
ItraconazoleThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Loratadine.Approved, Investigational
IvabradineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Ivabradine.Approved
IvacaftorThe serum concentration of Loratadine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Loratadine.Approved, Investigational, Vet Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Loratadine.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when Loratadine is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Loratadine.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Loratadine is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Loratadine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Loratadine.Approved, Investigational
KetotifenThe risk or severity of QTc prolongation can be increased when Ketotifen is combined with Loratadine.Approved
L-TryptophanThe risk or severity of adverse effects can be increased when Loratadine is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LacosamideThe risk or severity of adverse effects can be increased when Loratadine is combined with Lacosamide.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Loratadine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Loratadine is combined with Lamotrigine.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Loratadine is combined with Lanicemine.Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Loratadine.Approved, Investigational
LapatinibThe risk or severity of QTc prolongation can be increased when Lapatinib is combined with Loratadine.Approved, Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Loratadine is combined with Lasmiditan.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Loratadine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Loratadine.Approved
LenvatinibThe risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Loratadine.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Loratadine.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Leuprolide is combined with Loratadine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Loratadine is combined with Levetiracetam.Approved, Investigational
LevocabastineThe risk or severity of QTc prolongation can be increased when Levocabastine is combined with Loratadine.Approved, Investigational
LevocetirizineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Loratadine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Loratadine is combined with Levodopa.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Loratadine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of QTc prolongation can be increased when Levomethadyl Acetate is combined with Loratadine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Loratadine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Loratadine.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Loratadine.Approved
LincomycinThe risk or severity of adverse effects can be increased when Loratadine is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Loratadine is combined with Linezolid.Approved, Investigational
LisdexamfetamineLisdexamfetamine may decrease the sedative and stimulatory activities of Loratadine.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Loratadine is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Loratadine is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Lithium cation.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Loratadine is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Loratadine is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Loratadine can be increased when used in combination with Lofexidine.Approved, Investigational
LomefloxacinThe risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Loratadine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Loratadine.Approved
LopinavirThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loratadine is combined with Loprazolam.Experimental
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Loratadine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Loratadine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Loratadine is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Loratadine can be increased when it is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Loratadine is combined with Lortalamine.Experimental
LosartanThe serum concentration of Losartan can be increased when it is combined with Loratadine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Loratadine.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Loratadine.Approved
LuliconazoleThe serum concentration of Loratadine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Loratadine can be increased when combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Lumateperone.Investigational
LumefantrineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Loratadine.Approved, Investigational
LusutrombopagThe serum concentration of Lusutrombopag can be increased when it is combined with Loratadine.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Loratadine is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Loratadine is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Loratadine is combined with m-Chlorophenylpiperazine.Investigational
MacimorelinThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Macimorelin.Approved, Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium oxide.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium phosphate.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Loratadine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of QTc prolongation can be increased when Maprotiline is combined with Loratadine.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Loratadine is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Loratadine is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Loratadine is combined with Mebutamate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Loratadine is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Loratadine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Loratadine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Loratadine is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Loratadine is combined with Medifoxamine.Experimental
MefloquineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Loratadine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Loratadine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Loratadine is combined with Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Melperone.Approved, Investigational
MelphalanThe serum concentration of Melphalan can be increased when it is combined with Loratadine.Approved
MephedroneMephedrone may decrease the sedative and stimulatory activities of Loratadine.Investigational
MephenesinThe risk or severity of adverse effects can be increased when Loratadine is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Loratadine is combined with Mephenoxalone.Experimental
MephentermineMephentermine may decrease the sedative and stimulatory activities of Loratadine.Approved
MephenytoinThe risk or severity of adverse effects can be increased when Loratadine is combined with Mephenytoin.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Loratadine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Loratadine is combined with Meptazinol.Experimental
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Loratadine.Approved, Vet Approved
MequitazineThe risk or severity of QTc prolongation can be increased when Mequitazine is combined with Loratadine.Approved
MesoridazineThe risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Loratadine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Loratadine is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Loratadine is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Loratadine is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of QTc prolongation can be increased when Methadone is combined with Loratadine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Loratadine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative and stimulatory activities of Loratadine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Loratadine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Loratadine is combined with Metharbital.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Loratadine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Loratadine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Loratadine.Approved
MethotrimeprazineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Loratadine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative and stimulatory activities of Loratadine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Loratadine is combined with Methsuximide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Loratadine is combined with Methylene blue.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Loratadine is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Loratadine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Loratadine is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Loratadine.Approved, Vet Approved
MethyprylonThe risk or severity of adverse effects can be increased when Loratadine is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Loratadine is combined with Methysergide.Approved
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Loratadine.Approved, Investigational
MetocurineThe risk or severity of adverse effects can be increased when Loratadine is combined with Metocurine.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Loratadine is combined with Metocurine Iodide.Approved, Withdrawn
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Loratadine.Approved, Investigational
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Loratadine.Approved
MetyrosineLoratadine may increase the sedative activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Loratadine is combined with Mianserin.Approved, Investigational
MibefradilThe metabolism of Loratadine can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Loratadine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Loratadine is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Loratadine.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative and stimulatory activities of Loratadine.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Loratadine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Loratadine is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Loratadine is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved, Investigational
MirabegronThe risk or severity of QTc prolongation can be increased when Mirabegron is combined with Loratadine.Approved
MirtazapineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitomycinThe serum concentration of Mitomycin can be increased when it is combined with Loratadine.Approved
MitotaneThe serum concentration of Loratadine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Loratadine.Approved, Investigational
MivacuriumThe risk or severity of adverse effects can be increased when Loratadine is combined with Mivacurium.Approved
MK-212The risk or severity of adverse effects can be increased when Loratadine is combined with MK-212.Investigational
MMDAMMDA may decrease the sedative and stimulatory activities of Loratadine.Experimental, Illicit
MocetinostatThe risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Loratadine.Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Loratadine is combined with Moclobemide.Approved, Investigational
ModafinilThe serum concentration of Loratadine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of QTc prolongation can be increased when Moexipril is combined with Loratadine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Loratadine is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Loratadine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Loratadine is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Loratadine is combined with Mosapride.Investigational
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Loratadine.Approved, Investigational, Vet Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Loratadine.Approved, Investigational
MRK-409The risk or severity of adverse effects can be increased when Loratadine is combined with MRK-409.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Loratadine.Approved, Investigational
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Loratadine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Loratadine.Approved
NafcillinThe serum concentration of Loratadine can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Loratadine is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Loratadine.Approved
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Nalidixic Acid is combined with Loratadine.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Loratadine.Approved
NaloxoneThe metabolism of Loratadine can be decreased when combined with Naloxone.Approved, Vet Approved
NaluzotanThe risk or severity of adverse effects can be increased when Loratadine is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Loratadine is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Loratadine is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Loratadine is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Loratadine is combined with Nefiracetam.Investigational
NelfinavirThe risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Loratadine.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Nemonoxacin is combined with Loratadine.Investigational
NeocitrullamonThe risk or severity of adverse effects can be increased when Loratadine is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Loratadine is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Loratadine is combined with Neosaxitoxin.Investigational
NeostigmineThe serum concentration of Neostigmine can be increased when it is combined with Loratadine.Approved, Vet Approved
NetilmicinThe risk or severity of adverse effects can be increased when Loratadine is combined with Netilmicin.Approved, Investigational
NetupitantThe serum concentration of Loratadine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Loratadine can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Loratadine is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Niaprazine.Experimental
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Loratadine.Approved, Investigational
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Loratadine.Approved
NilotinibThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Loratadine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Loratadine.Approved
NisoxetineThe risk or severity of adverse effects can be increased when Loratadine is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Loratadine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Loratadine.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Loratadine.Approved
NomifensineThe risk or severity of adverse effects can be increased when Loratadine is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Loratadine is combined with Nordazepam.Approved
NorfloxacinThe risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Loratadine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Loratadine.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Loratadine is combined with Octamoxin.Withdrawn
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Loratadine.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Loratadine.Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Loratadine.Approved
OlanzapineThe risk or severity of QTc prolongation can be increased when Olanzapine is combined with Loratadine.Approved, Investigational
OlaparibThe metabolism of Loratadine can be decreased when combined with Olaparib.Approved
OlodaterolThe risk or severity of QTc prolongation can be increased when Olodaterol is combined with Loratadine.Approved
OlopatadineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Loratadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Loratadine.Approved, Investigational
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Loratadine.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Ondansetron is combined with Loratadine.Approved
OpipramolThe risk or severity of adverse effects can be increased when Loratadine is combined with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Loratadine is combined with Opium.Approved, Illicit
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Loratadine.Vet Approved
OrphenadrineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Loratadine is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Loratadine is combined with Osanetant.Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Loratadine is combined with Oxaflozane.Experimental
OxaliplatinThe risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Loratadine.Approved, Investigational
OxaprotilineThe risk or severity of adverse effects can be increased when Loratadine is combined with Oxaprotiline.Experimental
OxatomideThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Oxatomide.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Loratadine.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Loratadine is combined with Oxcarbazepine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Loratadine is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Loratadine is combined with Oxitriptan.Approved, Investigational, Nutraceutical
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Loratadine.Experimental
OxprenololThe risk or severity of adverse effects can be increased when Loratadine is combined with Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Loratadine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Loratadine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Loratadine is combined with Oxypertine.Experimental
OxytetracyclineThe risk or severity of adverse effects can be increased when Loratadine is combined with Oxytetracycline.Approved, Investigational, Vet Approved
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Loratadine.Approved, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Loratadine.Approved, Vet Approved
PalbociclibThe serum concentration of Loratadine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Paliperidone.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Loratadine is combined with Palonosetron.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Loratadine is combined with Pancuronium.Approved
PanobinostatThe risk or severity of QTc prolongation can be increased when Panobinostat is combined with Loratadine.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Loratadine.Approved
PapaverineThe risk or severity of QTc prolongation can be increased when Papaverine is combined with Loratadine.Approved, Investigational
ParaldehydeLoratadine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Loratadine is combined with Paramethadione.Approved
PargylineThe risk or severity of adverse effects can be increased when Loratadine is combined with Pargyline.Approved
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Loratadine.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Loratadine is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Loratadine is combined with Paroxetine.Approved, Investigational
PasireotideThe risk or severity of QTc prolongation can be increased when Pasireotide is combined with Loratadine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Loratadine.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Loratadine.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Loratadine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Loratadine is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Loratadine is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Loratadine is combined with Penimepicycline.Experimental
PentamidineThe risk or severity of QTc prolongation can be increased when Pentamidine is combined with Loratadine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Loratadine.Approved, Vet Approved
PentobarbitalThe metabolism of Loratadine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved
PerazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Perazine.Approved, Investigational
PerflutrenThe risk or severity of QTc prolongation can be increased when Perflutren is combined with Loratadine.Approved
PergolideThe risk or severity of adverse effects can be increased when Loratadine is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Loratadine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Loratadine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Loratadine.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Loratadine is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Loratadine is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Loratadine is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Loratadine is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Loratadine is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Loratadine is combined with Pheneturide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Loratadine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Pheniprazine.Withdrawn
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Loratadine.Approved
PhenobarbitalThe metabolism of Loratadine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Loratadine is combined with Phenoperidine.Experimental
PhenothiazineThe serum concentration of Phenothiazine can be increased when it is combined with Loratadine.Vet Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Loratadine is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Loratadine is combined with Phensuximide.Approved
PhenterminePhentermine may decrease the sedative and stimulatory activities of Loratadine.Approved, Illicit
PhenytoinThe metabolism of Loratadine can be increased when combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Loratadine.Approved, Investigational
PiclozotanThe risk or severity of adverse effects can be increased when Loratadine is combined with Piclozotan.Investigational
PimavanserinThe risk or severity of adverse effects can be increased when Loratadine is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Pimozide.Approved
PinazepamThe risk or severity of adverse effects can be increased when Loratadine is combined with Pinazepam.Experimental
PindololThe risk or severity of adverse effects can be increased when Loratadine is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Loratadine is combined with Pipecuronium.Approved
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Loratadine.Experimental
PipotiazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Loratadine is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Loratadine is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Loratadine is combined with Pirlindole.Approved
Piromidic acidThe risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Loratadine.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Loratadine.Approved
PitolisantThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Loratadine.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Loratadine is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Loratadine is combined with Pizotifen.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Loratadine is combined with Plazomicin.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Loratadine is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Loratadine is combined with Pomalidomide.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Loratadine.Approved, Investigational
PosaconazoleThe risk or severity of QTc prolongation can be increased when Posaconazole is combined with Loratadine.Approved, Investigational, Vet Approved
PracinostatThe risk or severity of QTc prolongation can be increased when Pracinostat is combined with Loratadine.Investigational
PramipexoleLoratadine may increase the sedative activities of Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Loratadine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Loratadine is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Loratadine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Loratadine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Loratadine.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Loratadine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Loratadine is combined with Pridinol.Experimental
PrimaquineThe risk or severity of QTc prolongation can be increased when Primaquine is combined with Loratadine.Approved
PrimidoneThe metabolism of Loratadine can be increased when combined with Primidone.Approved, Vet Approved
ProbucolThe risk or severity of QTc prolongation can be increased when Probucol is combined with Loratadine.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Loratadine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Loratadine.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Loratadine is combined with Progabide.Approved, Investigational
PromazineThe risk or severity of QTc prolongation can be increased when Promazine is combined with Loratadine.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Loratadine.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Loratadine.Approved
PropanididThe risk or severity of adverse effects can be increased when Loratadine is combined with Propanidid.Experimental
PropericiazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Propericiazine.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Propiomazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Propiopromazine.Vet Approved
PropofolThe risk or severity of QTc prolongation can be increased when Propofol is combined with Loratadine.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Loratadine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Loratadine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of QTc prolongation can be increased when Protriptyline is combined with Loratadine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Loratadine is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Loratadine.Approved
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Loratadine.Investigational
PRX-08066The risk or severity of adverse effects can be increased when Loratadine is combined with PRX-08066.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative and stimulatory activities of Loratadine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Loratadine is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Loratadine is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Loratadine is combined with Pyrantel.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Loratadine is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Loratadine.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Quetiapine.Approved
QuinidineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Loratadine is combined with Quinupramine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Loratadine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Loratadine is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Loratadine is combined with Ramosetron.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Loratadine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Loratadine.Approved, Investigational
RapacuroniumThe risk or severity of adverse effects can be increased when Loratadine is combined with Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Loratadine is combined with Rasagiline.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Loratadine is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Loratadine.Approved
RemacemideThe risk or severity of adverse effects can be increased when Loratadine is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Loratadine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Loratadine is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Loratadine is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Loratadine is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Loratadine is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Loratadine.Approved, Investigational
Rhodamine 6GThe serum concentration of Rhodamine 6G can be increased when it is combined with Loratadine.Experimental
RibociclibThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Ribociclib.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Loratadine is combined with Ribostamycin.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Ricolinostat is combined with Loratadine.Investigational
RifampicinThe metabolism of Loratadine can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Loratadine can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Loratadine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Loratadine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Loratadine.Approved
RiluzoleThe risk or severity of adverse effects can be increased when Loratadine is combined with Riluzole.Approved, Investigational
RimexoloneThe metabolism of Loratadine can be increased when combined with Rimexolone.Approved
RisperidoneThe risk or severity of QTc prolongation can be increased when Risperidone is combined with Loratadine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Loratadine is combined with Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative and stimulatory activities of Loratadine.Investigational
RitonavirThe risk or severity of QTc prolongation can be increased when Ritonavir is combined with Loratadine.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Loratadine.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Loratadine is combined with Rizatriptan.Approved
RocuroniumThe risk or severity of adverse effects can be increased when Loratadine is combined with Rocuronium.Approved
RolipramThe risk or severity of adverse effects can be increased when Loratadine is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Loratadine is combined with Rolitetracycline.Approved
RomidepsinThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Romidepsin.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Loratadine is combined with Romifidine.Vet Approved
RopiniroleLoratadine may increase the sedative activities of Ropinirole.Approved, Investigational
RosoxacinThe risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Loratadine.Approved, Investigational
RotigotineLoratadine may increase the sedative activities of Rotigotine.Approved
RoxithromycinThe risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Loratadine.Approved, Investigational, Withdrawn
RP-5063The risk or severity of adverse effects can be increased when Loratadine is combined with RP-5063.Investigational
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Loratadine.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Loratadine.Approved
RufloxacinThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Loratadine.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Rupatadine is combined with Loratadine.Approved
SafinamideThe risk or severity of adverse effects can be increased when Loratadine is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Safrazine.Withdrawn
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Loratadine.Approved, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Loratadine.Approved
SaquinavirThe risk or severity of QTc prolongation can be increased when Saquinavir is combined with Loratadine.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Loratadine.Vet Approved, Withdrawn
SaredutantThe risk or severity of adverse effects can be increased when Loratadine is combined with Saredutant.Investigational
SarilumabThe therapeutic efficacy of Loratadine can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Loratadine is combined with Sarpogrelate.Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Loratadine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Loratadine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Loratadine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Loratadine is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Loratadine.Approved
SerotoninThe risk or severity of adverse effects can be increased when Loratadine is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Loratadine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Loratadine is combined with Sertraline.Approved
SevofluraneThe risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Loratadine.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Loratadine is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Loratadine.Approved
SiltuximabThe serum concentration of Loratadine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Loratadine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Loratadine.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Loratadine.Approved, Investigational
SisomicinThe risk or severity of adverse effects can be increased when Loratadine is combined with Sisomicin.Investigational
SitafloxacinThe risk or severity of QTc prolongation can be increased when Sitafloxacin is combined with Loratadine.Experimental, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Loratadine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Loratadine.Approved
SolifenacinThe risk or severity of QTc prolongation can be increased when Solifenacin is combined with Loratadine.Approved
SomatostatinThe serum concentration of Somatostatin can be increased when it is combined with Loratadine.Approved, Investigational
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Loratadine.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Sotalol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Sparfloxacin.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Loratadine.Experimental
St. John's WortThe serum concentration of Loratadine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe serum concentration of Stanolone can be increased when it is combined with Loratadine.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Loratadine.Experimental
StiripentolThe serum concentration of Loratadine can be increased when it is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Loratadine is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Loratadine is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Loratadine is combined with Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Loratadine.Approved, Investigational
SulfamethoxazoleThe risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Loratadine.Approved
SulfisoxazoleThe risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Loratadine.Approved, Vet Approved
SulpirideThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Loratadine.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Loratadine is combined with Sulthiame.Experimental
SultoprideThe risk or severity of QTc prolongation can be increased when Sultopride is combined with Loratadine.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Loratadine is combined with Sumatriptan.Approved, Investigational
SunitinibThe risk or severity of QTc prolongation can be increased when Sunitinib is combined with Loratadine.Approved, Investigational
SuvorexantLoratadine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TacrineThe serum concentration of Tacrine can be increased when it is combined with Loratadine.Investigational, Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Loratadine.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Loratadine is combined with Talbutal.Approved, Illicit
TalinololThe serum concentration of Talinolol can be increased when it is combined with Loratadine.Investigational
TalopramThe risk or severity of adverse effects can be increased when Loratadine is combined with Talopram.Experimental
TamoxifenThe risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Loratadine.Approved
TandospironeThe risk or severity of adverse effects can be increased when Loratadine is combined with Tandospirone.Investigational
TandutinibThe risk or severity of QTc prolongation can be increased when Tandutinib is combined with Loratadine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Loratadine is combined with Tasimelteon.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Loratadine.Experimental
TD-8954The risk or severity of adverse effects can be increased when Loratadine is combined with TD-8954.Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Technetium Tc-99m ciprofloxacin is combined with Loratadine.Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Loratadine.Approved, Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Loratadine is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Loratadine is combined with Tegaserod.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Loratadine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinThe risk or severity of QTc prolongation can be increased when Telavancin is combined with Loratadine.Approved
TelithromycinThe risk or severity of QTc prolongation can be increased when Telithromycin is combined with Loratadine.Approved
TemafloxacinThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Temafloxacin.Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Loratadine.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Loratadine.Approved
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Loratadine.Approved
TerbutalineThe risk or severity of QTc prolongation can be increased when Terbutaline is combined with Loratadine.Approved
TerfenadineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Terfenadine.Approved, Withdrawn
TerlipressinThe risk or severity of QTc prolongation can be increased when Terlipressin is combined with Loratadine.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Terodiline.Experimental
Testosterone propionateThe serum concentration of Testosterone propionate can be increased when it is combined with Loratadine.Approved, Investigational, Vet Approved, Withdrawn
TetrabenazineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Tetrabenazine.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Loratadine is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tetrahydropalmatine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Loratadine is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Loratadine is combined with Tetrodotoxin.Investigational
ThalidomideLoratadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Loratadine is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Loratadine is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Loratadine is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Loratadine is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Loratadine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Loratadine.Approved, Withdrawn
ThiothixeneThe risk or severity of QTc prolongation can be increased when Thiothixene is combined with Loratadine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tiagabine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Loratadine is combined with Tiapride.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Loratadine.Approved
TigecyclineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tilidine.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Loratadine.Approved
TipranavirThe metabolism of Loratadine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of QTc prolongation can be increased when Tizanidine is combined with Loratadine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Loratadine is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Loratadine can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Loratadine is combined with Tofisopam.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Loratadine.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Tolperisone.Approved, Investigational
TolterodineThe risk or severity of QTc prolongation can be increased when Tolterodine is combined with Loratadine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Loratadine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Loratadine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Loratadine.Approved, Investigational
ToremifeneThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Loratadine.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Loratadine is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tranylcypromine.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Loratadine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Trazodone.Approved, Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Loratadine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Loratadine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Loratadine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Loratadine is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Loratadine is combined with Triclofos.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Loratadine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Loratadine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Loratadine is combined with Trimethadione.Approved
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Loratadine.Approved, Vet Approved
TrimipramineThe risk or severity of QTc prolongation can be increased when Trimipramine is combined with Loratadine.Approved
TriprolidineThe risk or severity of QTc prolongation can be increased when Triprolidine is combined with Loratadine.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Triptorelin is combined with Loratadine.Approved, Vet Approved
TroleandomycinThe metabolism of Loratadine can be decreased when combined with Troleandomycin.Approved
TropisetronThe risk or severity of adverse effects can be increased when Loratadine is combined with Tropisetron.Approved, Investigational
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tubocurarine.Approved
TucidinostatThe risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Loratadine.Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Loratadine.Approved, Investigational, Nutraceutical
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Loratadine.Approved
UrapidilThe risk or severity of adverse effects can be increased when Loratadine is combined with Urapidil.Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Loratadine is combined with Vabicaserin.Investigational
ValerianThe risk or severity of adverse effects can be increased when Loratadine is combined with Valerian.Approved, Experimental, Investigational
ValinomycinThe serum concentration of Valinomycin can be increased when it is combined with Loratadine.Experimental
ValnoctamideThe risk or severity of adverse effects can be increased when Loratadine is combined with Valnoctamide.Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Loratadine is combined with Valpromide.Experimental
ValspodarThe serum concentration of Valspodar can be increased when it is combined with Loratadine.Investigational
VancomycinThe risk or severity of adverse effects can be increased when Loratadine is combined with Vancomycin.Approved
VandetanibThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Vandetanib.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Vardenafil is combined with Loratadine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Loratadine is combined with Vecuronium.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Loratadine.Approved, Investigational
VemurafenibThe serum concentration of Loratadine can be decreased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Loratadine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Loratadine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Loratadine is combined with Veralipride.Experimental
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Loratadine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Loratadine is combined with Vigabatrin.Approved
VilanterolThe risk or severity of QTc prolongation can be increased when Vilanterol is combined with Loratadine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Loratadine is combined with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Loratadine is combined with Vinbarbital.Experimental
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Loratadine.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Loratadine.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Loratadine.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Loratadine.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Loratadine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Loratadine is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Loratadine is combined with Vinylbital.Experimental
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Loratadine.Approved, Investigational
VoriconazoleThe risk or severity of QTc prolongation can be increased when Voriconazole is combined with Loratadine.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Vorinostat is combined with Loratadine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Loratadine is combined with Vortioxetine.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Loratadine.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Loratadine is combined with Wortmannin.Experimental
XP19986The risk or severity of adverse effects can be increased when Loratadine is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Loratadine is combined with Xylazine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Loratadine is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Loratadine is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Loratadine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Loratadine is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Loratadine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Loratadine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Loratadine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Loratadine is combined with Zolmitriptan.Approved, Investigational
ZolpidemLoratadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Loratadine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Loratadine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Loratadine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take on empty stomach: 1 hour before or 2 hours after meals.

References

Synthesis Reference

Alberto Stampa, Pelayo Camps, Gloria Rodriguez, Jordi Bosch, Maria del Carmen Onrubia, "Process for the preparation of loratadine." U.S. Patent US6084100, issued July 04, 2000.

US6084100
General References
  1. See S: Desloratadine for allergic rhinitis. Am Fam Physician. 2003 Nov 15;68(10):2015-6. [PubMed:14655812]
  2. Menardo JL, Horak F, Danzig MR, Czarlewski W: A review of loratadine in the treatment of patients with allergic bronchial asthma. Clin Ther. 1997 Nov-Dec;19(6):1278-93; discussion 1523-4. [PubMed:9444440]
  3. Howarth PH: Histamine and asthma: an appraisal based on specific H1-receptor antagonism. Clin Exp Allergy. 1990 Aug;20 Suppl 2:31-41. [PubMed:1977506]
  4. Baroody FM, Naclerio RM: Antiallergic effects of H1-receptor antagonists. Allergy. 2000;55 Suppl 64:17-27. [PubMed:11291777]
External Links
Human Metabolome Database
HMDB0005000
KEGG Drug
D00364
PubChem Compound
3957
PubChem Substance
46507853
ChemSpider
3820
BindingDB
22876
ChEBI
6538
ChEMBL
CHEMBL998
Therapeutic Targets Database
DAP000101
PharmGKB
PA450266
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Loratadine
ATC Codes
R06AX13 — Loratadine
AHFS Codes
  • 04:08.00 — Second Generation Antihistamines
FDA label
Download (232 KB)
MSDS
Download (51.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentProgressive Multiple Sclerosis1
1CompletedOtherHealthy Volunteers2
1CompletedTreatmentHistamine H1 Antagonists, Non-Sedating1
1TerminatedTreatmentRheumatoid Arthritis1
2CompletedTreatmentAllergic Rhinitis (AR)2
2CompletedTreatmentBone Pain in Stage I - III Breast Cancer1
2CompletedTreatmentChronic Urticaria1
2CompletedTreatmentRhinitis, Allergic, Perennial1
2CompletedTreatmentRhinitis / Seasonal Rhinitis1
2RecruitingTreatmentTransplant, Kidney1
2Unknown StatusSupportive CarePegfilgrastim-induced Back and Leg Pain1
3Active Not RecruitingTreatmentRhinitis, Allergic, Seasonal1
3CompletedTreatmentAllergies / Conjunctivitis / Rhinitis / Rhinoconjunctivitis2
3CompletedTreatmentModerate or Severe Submental Fullness1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
3CompletedTreatmentRhinitis, Allergic, Seasonal1
3CompletedTreatmentSeasonal Allergic Rhinitis (SAR)6
4CompletedOtherHealthy Volunteers1
4CompletedTreatmentAllergic Rhinitis (AR)1
4CompletedTreatmentAllergic Rhinitis (AR) / Pollen Allergy / Rhinitis, Allergic, Seasonal / Severe Acute Respiratory Syndrome1
4CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
4CompletedTreatmentRhinitis2
4CompletedTreatmentRhinitis, Allergic, Perennial1
4CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
Not AvailableCompletedNot AvailableLeukemias / Malignant Lymphomas1
Not AvailableCompletedNot AvailablePruritus / Rhinitis, Allergic, Perennial / Rhinitis, Allergic, Seasonal / Urticarias1
Not AvailableNot Yet RecruitingTreatmentRhinitis, Allergic, Perennial1
Not AvailableRecruitingTreatmentMalignant Lymphomas1

Pharmacoeconomics

Manufacturers
  • Schering plough healthcare products inc
  • Taro pharmaceuticals usa inc
  • Apotex inc richmond hill
  • L perrigo co
  • Ranbaxy laboratories ltd
  • Silarx pharmaceuticals inc
  • Taro pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Wockhardt eu operations (swiss) ag
  • Wyeth consumer healthcare
  • Impax laboratories inc
  • Watson laboratories inc florida
  • Apotex inc etobicoke site
  • Mylan pharmaceuticals inc
  • Perrigo co
  • Sandoz inc
Packagers
  • Amerisource Health Services Corp.
  • AstraZeneca Inc.
  • Cardinal Health
  • Catalent Pharma Solutions
  • Chain Drug
  • Concern Stirol
  • CVS Pharmacy
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • H.J. Harkins Co. Inc.
  • Major Pharmaceuticals
  • Merck & Co.
  • Neuman Distributors Inc.
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Patient First Corp.
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Professional Co.
  • S&P Healthcare
  • Southwood Pharmaceuticals
  • Walgreen Co.
  • West-Ward Pharmaceuticals
  • Wockhardt Ltd.
  • Wyeth Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral10 mg/1
LiquidOral5 mg/5mL
SolutionOral5 mg/5mL
Tablet, chewableOral5 mg/1
Tablet, multilayer, extended releaseOral
Tablet, orally disintegratingOral10 mg
Tablet, orally disintegratingOral5 mg
Tablet, orally disintegratingOral5 mg/1
SyrupOral1 mg
Tablet, extended releaseOral
Capsule, liquid filledOral10 mg/1
Tablet, orally disintegratingOral10 mg/1
Tablet, film coated, extended releaseOral
CapsuleOral10 mg
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral
Prices
Unit descriptionCostUnit
Claritin 30 10 mg tablet Box29.99USD box
Lisinopril 100% powder21.6USD g
Zestril 40 mg tablet2.48USD tablet
Claritin-d 12 hour tablet sa2.46USD tablet
Prinivil 40 mg tablet2.4USD tablet
Zestril 30 mg tablet2.4USD tablet
Zestril 5 mg tablet1.54USD tablet
Lisinopril 30 mg tablet1.51USD tablet
Claritin 10 mg tablet1.48USD tablet
Claritin-d 24 hour tablet sa1.43USD tablet
Zestril 10 mg tablet1.43USD tablet
Claritin 10 mg reditabs1.4USD tablet
Lisinopril 40 mg tablet1.26USD tablet
Zestril 20 mg tablet1.25USD tablet
Prinivil 20 mg tablet1.23USD tablet
Prinivil 10 mg tablet1.15USD tablet
Loratadine-d 24hr tablet1.11USD tablet
Prinivil 5 mg tablet1.11USD tablet
Lisinopril 20 mg tablet1.07USD tablet
Child's claritin 5 mg tablet chew1.02USD tablet
Lisinopril 10 mg tablet0.99USD tablet
Lisinopril 5 mg tablet0.96USD tablet
CVS Pharmacy loratadine-d 24hr tablet0.89USD tablet
Zestril 2.5 mg tablet0.79USD tablet
Tavist nd 10 mg tablet0.74USD tablet
Wal-itin 10 mg tablet0.7USD tablet
Alavert d-12 allergy-sinus tablet0.68USD tablet
Alavert 10 mg tablet0.64USD tablet
Lisinopril 2.5 mg tablet0.64USD tablet
CVS Pharmacy loratadine 10 mg tablet0.52USD tablet
Loratadine 10 mg tablet0.47USD tablet
CVS Pharmacy allergy relief 10 mg tablet0.44USD tablet
Qc loratadine 10 mg tablet0.08USD tablet
Allergy relief 10 mg tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6132758No1998-06-012018-06-01Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)134-136 °CPhysProp
water solubility0.000011 mg/mlNot Available
logP5.20SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0134 mg/mLALOGPS
logP4.8ALOGPS
logP4.55ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)4.33ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area42.43 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity116.98 m3·mol-1ChemAxon
Polarizability41.67 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9754
Caco-2 permeable-0.5488
P-glycoprotein substrateSubstrate0.7337
P-glycoprotein inhibitor IInhibitor0.9505
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterNon-inhibitor0.5143
CYP450 2C9 substrateNon-substrate0.8197
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.677
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9359
Ames testNon AMES toxic0.6884
CarcinogenicityNon-carcinogens0.915
BiodegradationNot ready biodegradable0.9963
Rat acute toxicity2.8964 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7531
hERG inhibition (predictor II)Inhibitor0.8456
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001r-1279000000-1c522c39e53b6bbfb9aa
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001r-0039000000-928ed9c6b46ba83ebe20
MS/MS Spectrum - , positiveLC-MS/MSsplash10-067r-1292000000-3869907bd01f927b6f22
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzocycloheptapyridines. These are aromatic compounds containing a benzene ring and a pyridine ring fused to a seven membered carbocycle.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzocycloheptapyridines
Sub Class
Not Available
Direct Parent
Benzocycloheptapyridines
Alternative Parents
Piperidinecarboxylic acids / Pyridines and derivatives / Benzenoids / Aryl chlorides / Heteroaromatic compounds / Carbamate esters / Organic carbonic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 4 more
Substituents
Benzocycloheptapyridine / Piperidinecarboxylic acid / Aryl chloride / Aryl halide / Piperidine / Pyridine / Benzenoid / Heteroaromatic compound / Carbamic acid ester / Carbonic acid derivative
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Details
1. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Cieslewicz G, Gondorowicz K, Grzelewska-Rzymowska I, Rozniecki J, Wojciechowska B: [Effect of loratadine--selective antagonist of histamine (H1) receptor--on allergen-induced bronchoconstriction in atopic asthmatics]. Pneumonol Alergol Pol. 1992;60(11-12):11-5. [PubMed:1303772]
  3. Cieslewicz G, Gondorowicz K, Grzelewska-Rzymowska I, Rozniecki J: [Effect of loratadine, selective antagonist of histamine H1 receptors, on histamine-induced bronchoconstriction]. Pneumonol Alergol Pol. 1995;63(5-6):281-5. [PubMed:7581058]
  4. Letari O, Miozzo A, Folco G, Belloni PA, Sala A, Rovati GE, Nicosia S: Effects of loratadine on cytosolic Ca2+ levels and leukotriene release: novel mechanisms of action independent of the anti-histamine activity. Eur J Pharmacol. 1994 Feb 15;266(3):219-27. [PubMed:8174605]
  5. Cavero I, Mestre M, Guillon JM, Heuillet E, Roach AG: Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans? Drug Saf. 1999;21 Suppl 1:19-31; discussion 81-7. [PubMed:10597865]
  6. Tamura T, Masaki S, Ohmori K, Karasawa A: Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice. Pharmacology. 2005 Dec;75(1):45-52. Epub 2005 Jun 7. [PubMed:15942272]
  7. Grzelewska-Rzymowska I, Gondorowicz K, Cieslewicz G, Rozniecki J, Wojciechowska B: [Effect of loratadine (LO), a selective H1 antagonist, on histamine-induced bronchoconstriction]. Pneumonol Alergol Pol. 1992;60(11-12):16-21. [PubMed:1303773]
  8. Menardo JL, Horak F, Danzig MR, Czarlewski W: A review of loratadine in the treatment of patients with allergic bronchial asthma. Clin Ther. 1997 Nov-Dec;19(6):1278-93; discussion 1523-4. [PubMed:9444440]
  9. Howarth PH: Histamine and asthma: an appraisal based on specific H1-receptor antagonism. Clin Exp Allergy. 1990 Aug;20 Suppl 2:31-41. [PubMed:1977506]
  10. Baroody FM, Naclerio RM: Antiallergic effects of H1-receptor antagonists. Allergy. 2000;55 Suppl 64:17-27. [PubMed:11291777]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Crumb WJ Jr: Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions. J Pharmacol Exp Ther. 2000 Jan;292(1):261-4. [PubMed:10604956]
  2. Taglialatela M, Pannaccione A, Castaldo P, Giorgio G, Zhou Z, January CT, Genovese A, Marone G, Annunziato L: Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol. 1998 Jul;54(1):113-21. [PubMed:9658196]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Warzecha H, Ferme D, Peer M, Frank A, Unger M: Bioconversion of the antihistaminc drug loratadine by tobacco cell suspension cultures expressing human cytochrome P450 3A4. J Biosci Bioeng. 2010 Mar;109(3):288-90. doi: 10.1016/j.jbiosc.2009.09.001. Epub 2009 Sep 29. [PubMed:20159579]
  2. Li C, Lee MY, Choi JS: Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats. Pharmazie. 2010 Jul;65(7):510-4. [PubMed:20662320]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Barecki ME, Casciano CN, Johnson WW, Clement RP: In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1173-5. [PubMed:11502723]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Barecki ME, Casciano CN, Johnson WW, Clement RP: In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1173-5. [PubMed:11502723]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos. 2001 Aug;29(8):1080-3. [PubMed:11454724]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:40